evaluations+economics

With real-world data in hand, the Institute for Clinical and Economic Review (ICER) is retooling its cost-effectiveness models for three rare disease drugs. And the new discounts it has in mind are steep.

Coronavirus vaccines provided strong protection against infection for essential workers earlier this year, but have become less effective.

The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy.

Reflecting Poorly: Health Care in the U.S. Compared to Other High-Income Countries

NICE is changing how it assess new drugs, devices, diagnostics and digital technologies to provide faster and fairer access in the NHS. The changes will also improve the way it works with patients, the NHS and the life sciences industry.

Medicare negotiation and inflation rebates would likely have the unintended effect of modestly lowering the rebates manufacturers must now pay state Medicaid programs, thereby raising federal and state Medicaid prescription drug costs.

The pharmaceutical industry has long argued that high drug prices reflect the high cost of innovation and that reducing drug prices would necessarily slow the pipeline of new drugs.

New research shows that drug price reductions under the US’s H.R. 3 policy could have no impact on innovation in the pharmaceutical industry.

The debate over a budget reconciliation package in the coming weeks, and possibly months, is likely to focus heavily on the savings to Medicare, which can be used to expand Medicare benefits and fund other health care priorities.

The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s disease.

Stunning reversals, surprise delays and controversial approvals are the order of the day at the FDA lately — and doctors have had enough.

A preponderance of evidence proves the virus that caused the COVID-19 pandemic leaked from a Chinese research facility, said a report by U.S. Republicans released on Monday.

High biologic drug prices have placed substantial strain on the US health care system.

France has a single-payer health insurance system that has the authority to impose pharmaceutical price reductions but relies on decentralized market negotiations between hospitals and manufacturers to establish prices for injected and infused biologics.

The continuing launch of innovative but high-price drugs has intensified efforts by payers to manage use and spending and by pharmaceutical manufacturers to support patient access and sales.